港股异动丨必瘦站(01830.HK)绩前抢跑 升近6%破顶 近2月累计涨60%
格隆汇11月27日丨必瘦站(01830.HK)尾盘涨幅扩大,现升5.81%,高见3.7港元创历史新高价,近2月累计涨60%。暂成交1804万港元,总市值44.55亿港元。公司将于11月30日举行董事会会议,审核中期业绩,以及考虑派付中期股息(如有)。但此前公司预计中期纯利下跌约40%-45%。另外,本月中旬公司公布,鉴于卫生事件转趋稳定,11月首11日‘双十一购物节’集团整体销售合同按年上升44.2%。其中,香港销售合同按年上升43.1%;内地、澳门及澳洲则增长47%。董事会认为,集团的整体财务状况仍然维持稳健。展望将来,集团对未来几个季度的业务表现感到乐观。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.